Schizophrenia & Other Psychotic Disorders
Evidence-Based Reviews
Cannabis, synthetic cannabinoids, and psychosis risk: What the evidence says
Research suggests marijuana may be a ‘component cause’ of psychosis
Commentary
Reserpine for schizophrenia
Cases That Test Your Skills
‘Scared’ and short of breath
While being treated for paranoid schizophrenia, Mr. C, age 42, suddenly develops a fever, high blood pressure, and altered mental status. How...
Cases That Test Your Skills
Unexpected improvement
For 30 years, Ms. U, age 53, has experienced treatment-resistant schizophrenia. After she is treated for a neurologic disorder, her psychotic...
Podcasts
How to assess for possible drug-drug interactions
Marie A. Yu, PharmD
Cases That Test Your Skills
A dangerous GI complication
Ms. X, age 61, undergoes emergent surgery for intestinal obstruction. Her paranoid schizophrenia has been well controlled on clozapine, but the...
News
FDA, Company Announce Risperidone Recall
Podcasts
How to best help patients with residual schizophrenia symptoms
Leslie Citrome, MD, MPH
Evidence-Based Reviews
Treatment-resistant schizophrenia: What can we do about it?
Use pharmacotherapy and other interventions to target the symptoms that matter most to your patient
Pearls
The ABCs of estimating adherence to antipsychotics
Your patient’s adherence to a medication regimen is both an attitude and a behavior, and you need to assess both
Pearls
Evaluating medication outcomes: 3 key questions
To avoid incorrectly attributing adverse outcomes to a medication, carefully evaluate any potential confounding factors